Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Neoadjuvant RCT Versus CT for Patients With Locally Advanced, Potentially Resectable Adenocarcinoma of the GEJ

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04375605
Recruitment Status : Recruiting
First Posted : May 5, 2020
Last Update Posted : June 5, 2020
Sponsor:
Collaborators:
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Deutsche Krebshilfe e.V., Bonn (Germany)
Information provided by (Responsible Party):
Ralf Hofheinz, Universitätsmedizin Mannheim

Brief Summary:
This is a multicenter, prospective, randomized, stratified, controlled, open-label study comparing neoadjuvant radiochemotherapy with FLOT versus FLOT chemotherapy alone für patients with locally advanced, potentially resectable adenocarcinoma of the gastroesophageal junction (GEJ)

Condition or disease Intervention/treatment Phase
Gastroesophageal Junction Adenocarcinoma Drug: 5-Fluorouracil Drug: Calcium folinate Drug: Oxaliplatin Drug: Docetaxel Radiation: Radiation Drug: Oxaliplatin during radiotherapy Drug: 5-Fluorouracil during radiotherapy Phase 3

Detailed Description:

The RACE trial seeks to demonstrate superiority of preoperative FLOT induction chemotherapy followed by preoperative radiochemotherapy and postoperative FLOT chemotherapy over perioperative FLOT chemotherapy without radiotherapy in patients with adenocarcinoma of the gastroesophageal junction undergoing adequate oncological surgery.

Eligible patients will be randomly allocated to one of two treatment groups, i.e. preoperative chemotherapy (Arm A) or preoperative chemotherapy with subsequent preoperative radiochemotherapy (arm B), both followed by resection and postoperative completion of chemotherapy. Randomization will occur in a 1:1 ratio with stratification by primary tumor site (Siewert I vs. Siewert II/III).

Arm A:

Patients randomized to Arm A (control arm) will be treated with four preoperative cycles of FLOT. Cycles will be repeated every two weeks. The preoperative chemotherapy duration in Arm A is eight weeks. Surgical resection will follow 4-6 weeks after day 1 of the last cycle of neoadjuvant therapy. Postoperative chemotherapy will start 6-12 weeks after surgery and consists of another four cycles of FLOT every two weeks. The total treatment period is 25-32 weeks.

Arm B:

Patients randomized in Arm B (experimental arm) will be treated with two cycles of FLOT every two weeks. Radiochemotherapy will start three weeks after day 1 of the second cycle and consists of oxaliplatin and infusional 5-fluorouracil plus concurrent radiotherapy given to a dose of 45 Gy (25 daily fractions with 1.8 Gy) over five weeks. The preoperative treatment duration is 10 weeks. Surgical resection will follow 4-6 weeks after last treatment with chemotherapy / radiation. Postoperative chemotherapy will start 6-12 weeks after surgery and consists of four cycles of FLOT every two weeks. The total treatment period is 26-33 weeks.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 340 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: RACE-trial: Neoadjuvant Radiochemotherapy Versus Chemotherapy for Patients With Locally Advanced, Potentially Resectable Adenocarcinoma of the Gastroesophageal Junction (GEJ) A Randomized Phase III Joint Study of the AIO, ARO and DGAV
Actual Study Start Date : June 3, 2020
Estimated Primary Completion Date : May 2028
Estimated Study Completion Date : August 2028

Resource links provided by the National Library of Medicine

Drug Information available for: Leucovorin

Arm Intervention/treatment
Active Comparator: Arm A (control arm)
Patients randomized in control arm A will receive four cycles of neoadjuvant chemotherapy with FLOT every two weeks (5-FU 2600 mg/m² d1, leucovorin 200 mg/m² d1, oxaliplatin 85 mg/m² d1, docetaxel 50 mg/m² d1) followed by surgical resection 4-6 weeks after day 1 of the last cycle of neoadjuvant therapy. 6-12 weeks after surgery adjuvant chemotherapy starts with 4 cycles of FLOT (total treatment period 25-32 weeks).
Drug: 5-Fluorouracil
Day 1 q2w: 2600 mg/m² IV over 24 hours

Drug: Calcium folinate
Day 1 q2w: 200 mg/m² IV over 2 hours
Other Name: Leucovorin

Drug: Oxaliplatin
Day 1 q2w: 85 mg/m² IV over 2 hours

Drug: Docetaxel
Day 1 q2w: 50 mg/m² IV over 2 hours

Experimental: Arm B (experimental arm)
Patients randomized in experimental arm B will receive two cycles of neoadjuvant induction chemotherapy with FLOT (5-FU 2600 mg/m² d1, leucovorin 200 mg/m² d1, oxaliplatin 85 mg/m² d1, docetaxel 50 mg/m² d1) every two weeks (4 weeks of therapy) followed by radiochemo-therapy beginning at day 21 after day one of the last cycle of chemotherapy. Radiochemotherapy consists of oxaliplatin 45 mg/m² weekly (d1, 8, 15, 22, 29) and continuous infusional 5-FU 225 mg/m² plus concurrent radiotherapy given in 5/week fractions with 1.8 Gy to a dose of 45 Gy over 5 weeks. Resection is performed 4-6 weeks after last treatment with chemotherapy / radiation. Adjuvant treatment starts 6-12 weeks after surgery and consists of 4 cycles of FLOT (total treatment period of 26 - 33 weeks).
Drug: 5-Fluorouracil
Day 1 q2w: 2600 mg/m² IV over 24 hours

Drug: Calcium folinate
Day 1 q2w: 200 mg/m² IV over 2 hours
Other Name: Leucovorin

Drug: Oxaliplatin
Day 1 q2w: 85 mg/m² IV over 2 hours

Drug: Docetaxel
Day 1 q2w: 50 mg/m² IV over 2 hours

Radiation: Radiation
25 fractions (5 each week over 5 weeks) each 1,8 Gy to a total of 45 Gy

Drug: Oxaliplatin during radiotherapy
Day 1, 8, 15, 22, 29: 45 mg/m² IV over 2 hours

Drug: 5-Fluorouracil during radiotherapy
day 1 - 33: 225 mg/m²/day IV continuously




Primary Outcome Measures :
  1. Comparison of PFS between arms [ Time Frame: up to 5 years ]
    to compare PFS in patients with resectable GEJ adenocarcinoma receiving perioperative FLOT alone versus perioperative FLOT combined with neoadjuvant radiochemotherapy where PFS ist defined as the time from randomization to disease progression or disease recurrence after surgery or death from any cause


Secondary Outcome Measures :
  1. Overall survival (OS) [ Time Frame: up to 5 years ]
    Overall survival (OS) where OS is defined as the time from randomization to death from any cause

  2. R0 resection rate [ Time Frame: after surgery, approx. 12 weeks after randomization ]
    R0 resection rate where R0 resection is defined as microscopically margin negative resection with no gross or microscopic tumor remains in the areas of the primary tumor and/or samples regianal lymph nodes based on evaluation by the local pathologist.

  3. Number of harvested lymph nodes [ Time Frame: after surgery, approx. 12 weeks after randomization ]
    Number of harvested lymph nodes during surgery

  4. Site of tumor relapse [ Time Frame: 5 years ]
    Site of tumor relapse if tumor recurrence/relapse occurs

  5. Overall survival rate at 1, 3 and 5 years [ Time Frame: 1 year, 3 years, 5 years ]
    Overall survival rate is defined as the proportion of patients known to be alive at 1, 3 or 5 years after randomization

  6. Patient reported outcomes: quality of life according to questionnaire EORTC-QLQ-C30 [ Time Frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to approximately 68 months ]
    quality of life scores according to validated questionnaires EORTC-QLQ-C30

  7. Patient reported outcomes: quality of life according to questionnaire EORTC module OG25 [ Time Frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to approximately 68 months ]
    quality of life scores according to validated questionnaire EORTC module OG25



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Histologically proven, locally advanced and potentially resectable adenocarcinoma of the gastroesophageal junction (GEJ) (Siewert I- III) that is: cT3-4, any N, M0 or cT2 N+, M0 according to AJCC 8th edition
  2. Patients* must be candidates for potential curative resection as determined by the treating surgeon
  3. ECOG performance status 0-1
  4. Age 18 years or above
  5. Adequate hematologic function with absolute neutrophil count (ANC) ≥ 1.5 x 10^9/l, platelets ≥ 100 x 10^9/l and hemoglobin ≥ 9.0 mg/dl
  6. INR <1.5 and aPTT<1.5 x upper limit of normal (ULN) within 7 days prior to starting study treatment
  7. Adequate liver function as measured by serum transaminases (ASAT, ALAT) ≤ 2.5 x ULN and total bilirubin ≤ 1.5 x ULN
  8. Adequate renal function with serum creatinine ≤ 1.5 x ULN
  9. QTc interval (Bazett*) ≤ 440 ms
  10. Written informed consent obtained before randomization
  11. Negative pregnancy test for women of childbearing potential within 7 days of commencing study treatment. Males and females of reproductive potential must agree to practice highly effective*** contraceptive measures during the study and for 6 months after the end of study treatment. Male patients must also agree to refrain from father a child during treatment and up to 6 months afterwards and additionally to use a condom during treatment period. Their female partner of childbearing potential must also agree to use an adequate contraceptive measure.

    • *There are no data that indicate special gender distribution. Therefore, patients will be enrolled in the study gender-independently.
    • ** formula for QTc interval calculation (Bazett): QTc= ((QT) ̅" (ms)" )/√(RR (sec))= ((QT) ̅" (ms)" )/√(60/(Frequence (1/min)))
    • *** highly effective (i.e. failure rate of <1% per year when used consistently and correctly) methods: intravaginal and transdermal combined (estrogen and progestogen containing) hormonal contraception; injectable and implantable progestogen-only hormonal contraception; intrauterine device (IUD); intrauterine hormone-releasing system (IUS); bilateral tubal occlusion; vasectomised partner; sexual abstinence (complete abstinence is defined as refraining from heterosexual intercourse during the entire period of risk associated with the study treatments).

Exclusion Criteria:

  1. Evidence of metastatic disease (exclusion of distant metastasis by CT of thorax and abdomen, bone scan or MRI [if osseous lesions are suspected due to clinical signs])
  2. Past or current history (within the last 5 years prior to treatment start) of other malignancies. Patients with curatively treated basal and squamous cell carcinoma of the skin or in situ carcinoma of the cervix are eligible
  3. Evidence of peripheral sensory neuropathy > grade 1 according to CTCAE version 4.03
  4. Patients with other significant underlying medical conditions that may be aggravated by the study treatment or are not controlled
  5. Pregnant or lactating females
  6. Patients medically unfit for chemotherapy and radiotherapy
  7. Patients receiving any immunotherapy, cytotoxic chemotherapy or radiotherapy other than defined by the protocol. The participation in another clinical trial with the use of investigational agents, chemotherapy or radiotherapy during the trial is not permitted
  8. Known hypersensitivity against 5-FU, leucovorin, oxaliplatin or docetaxel
  9. Other known contraindications against 5-FU, leucovorin, oxaliplatin, or docetaxel
  10. Clinically significant active coronary heart disease, cardiomyopathy or congestive heart failure, NYHA III-IV
  11. Clinically significant valvular defect
  12. Other severe internal disease or acute infection
  13. Peripheral polyneuropathy > NCI Grade II according to CTCAE version 4.03
  14. Chronic inflammatory bowel disease

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04375605


Contacts
Layout table for location contacts
Contact: Ralf-Dieter Hofheinz, Prof. Dr. +49 621 383 ext 2855 ralf.hofheinz@umm.de
Contact: Martin Walker +49 69 7601 ext 4571 walker.martin@ifk-khnw.de

Locations
Layout table for location information
Germany
Unversity Hospital Mannheim Recruiting
Mannheim, Germany, 68167
Contact: Ralf Hofheinz, Prof.    +49 621 383 2855    Ralf.Hofheinz@umm.de   
Sponsors and Collaborators
Universitätsmedizin Mannheim
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Deutsche Krebshilfe e.V., Bonn (Germany)
Investigators
Layout table for investigator information
Principal Investigator: Ralf-Dieter Hofheinz, Prof. Dr. Universitätsmedizin Mannheim
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Ralf Hofheinz, Prof. Dr. med., Universitätsmedizin Mannheim
ClinicalTrials.gov Identifier: NCT04375605    
Other Study ID Numbers: RACE
2018-001728-20 ( EudraCT Number )
AIO-STO-0118 ( Other Identifier: Arbeitsgemeinschaft Internistische Onkologie )
First Posted: May 5, 2020    Key Record Dates
Last Update Posted: June 5, 2020
Last Verified: June 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Adenocarcinoma
Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Leucovorin
Docetaxel
Fluorouracil
Oxaliplatin
Calcium
Levoleucovorin
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Calcium-Regulating Hormones and Agents
Physiological Effects of Drugs
Antimetabolites
Antimetabolites, Antineoplastic
Immunosuppressive Agents
Immunologic Factors
Antidotes
Protective Agents
Vitamin B Complex
Vitamins
Micronutrients
Nutrients
Growth Substances